For hours Friday, people waited to address the U.S. Food and Drug Administration about cannabis and cannabidiol, the new and largely unregulated compound that’s showing up in everything from cookies to dog treats. Lawyers, manufacturers, lab operators, advocates of those with debilitating diseases—they all had something to say.
The FDA called the public comment session as a precursor to potential regulation of hemp-derived cannabidiol, or CBD, an increasingly popular additive that is projected by New Frontier Data to reach nearly $1.3 billion in U.S. sales by 2022. As the hearing stretched into its ninth hour, a panel of FDA officials had already heard from 100 speakers, including those who want more labeling, testing and dosing requirements and others who want the agency to take a much lighter regulatory touch.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
